Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Jul;97(Suppl 1):17–20.

Intravenous immune globulin in chronic lymphocytic leukaemia.

H Gamm 1, C Huber 1, H Chapel 1, M Lee 1, F Ries 1, M A Dicato 1
PMCID: PMC1550375  PMID: 8033428

Abstract

The most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patients. A randomized, double-blind study on 36 patients receiving either 500 mg/kg or 250 mg/kg IVIG every 4 weeks was undertaken to determine the dose regimen required. There was no significant difference in the two treatment groups and we found that CLL patients were equally protected with low-dose IVIG.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Besa E. C. Recent advances in the treatment of chronic lymphocytic leukemia: defining the role of intravenous immunoglobulin. Semin Hematol. 1992 Jul;29(3 Suppl 2):14–23. [PubMed] [Google Scholar]
  2. Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198–206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  3. Boggs D. R., Sofferman S. A., Wintrobe M. M., Cartwright G. E. Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med. 1966 Feb;40(2):243–254. doi: 10.1016/0002-9343(66)90105-7. [DOI] [PubMed] [Google Scholar]
  4. Chapel H. M., Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol. 1987 Oct;24(4):291–296. [PubMed] [Google Scholar]
  5. Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov;29(3):152–163. doi: 10.1002/ajh.2830290307. [DOI] [PubMed] [Google Scholar]
  6. Dicato M., Chapel H., Gamm H., Lee M., Ries F., Marichal S., Wirth C., Griffith H., Brennan V. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. Cancer. 1991 Sep 15;68(6 Suppl):1437–1439. doi: 10.1002/1097-0142(19910915)68:6+<1437::aid-cncr2820681406>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  7. Dighiero G., Travade P., Chevret S., Fenaux P., Chastang C., Binet J. L. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood. 1991 Oct 15;78(8):1901–1914. [PubMed] [Google Scholar]
  8. Geisler C. H., Philip P., Hansen M. M. B-cell chronic lymphocytic leukaemia: clonal chromosome abnormalities and prognosis in 89 cases. Eur J Haematol. 1989 Nov;43(5):397–403. doi: 10.1111/j.1600-0609.1989.tb00326.x. [DOI] [PubMed] [Google Scholar]
  9. Juliusson G., Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet. 1990 Apr;45(2):143–160. doi: 10.1016/0165-4608(90)90079-p. [DOI] [PubMed] [Google Scholar]
  10. Juliusson G., Oscier D. G., Fitchett M., Ross F. M., Stockdill G., Mackie M. J., Parker A. C., Castoldi G. L., Guneo A., Knuutila S. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990 Sep 13;323(11):720–724. doi: 10.1056/NEJM199009133231105. [DOI] [PubMed] [Google Scholar]
  11. Lee J. S., Dixon D. O., Kantarjian H. M., Keating M. J., Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood. 1987 Mar;69(3):929–936. [PubMed] [Google Scholar]
  12. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  13. Rozman C., Montserrat E., Rodríguez-Fernández J. M., Ayats R., Vallespí T., Parody R., Ríos A., Prados D., Morey M., Gomis F. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984 Sep;64(3):642–648. [PubMed] [Google Scholar]
  14. Rozman C., Montserrat E., Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988 Jan 15;61(2):279–283. doi: 10.1002/1097-0142(19880115)61:2<279::aid-cncr2820610215>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES